Teva spinout delays NASH IPO while Galera prices below range
A NASH-focused spinoff of Teva Pharmaceuticals delayed its IPO and Galera priced below its $14-$16 range as the public waters grow murkier.
Touting an FGF21 …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
